syngeneic lymphocytes cultured with okt3 and interleukin-2

Cell therapyexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 1996 (NCT00001535)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetImmunity, passive

    immunity, passive

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • syngeneic lymphocytes cultured with okt3 and interleukin-2

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00001535Phase 1Mar 1, 1996National Human Genome Research Institute (NHGRI)
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Human Genome Research Institute (NHGRI)Government1111996
1 organizations
Page 1 / 1